what year will next medi new product launch ?

nutin till 2020 rite ? just five years away ?

 

I'm betting on 2114. it will take about 100 years.

 

Haven't been watching too closely have you? Tsk tsk. See asco.

 

when will the BLA on all of the asco products be filed, must be this year right ??

 

Another year passes.... Medi talks more "someday we will make a drug"... not this year, not next year.... just give us money

 

couldn't get a Medi job huh? So sorry...not!

 

Seriously, medi talks shit but actually they perform like shit. What fucking drug has medi gotten approved in the last five years ? Hey stupid ass - what's the answer ??

 

Keep your eyes on 4736

 

dude you say it will be over 2000 years until the next medi product launch ?

 

Wait here, I'm still thinking.

 

crickets chirp as the silence descends... launch a product ? we dont do that !!

 

Last Medi launch was Quad Flu both in US and then EU. Next will file BLA in 2015 and two in 2016. Launches in 2016/17.

 

douche bag update a market lagging flu vaccine isn't a "new product launch"

FluMist Quadrivalent is similar to MedImmune's trivalent influenza vaccine, except FluMist Quadrivalent provides protection against an additional influenza strain

 

Market lagging? Oh dear sweet lad, take a look at how fm owns the market for kids that dont have other disqualifying health issues. You poor sweet uninformed little brain.

 

The three biggest suppliers for the US market, Sanofi Pasteur, GSK, and Novartis, announced the start of vaccine shipments this month. Three others—MedImmune, bioCSL, and Protein Sciences—expect to start shipping their products soon.

One new wrinkle this year is that the ACIP, which develops federal immunization advice, expressed a preference for use of the intranasal vaccine (FluMist, made by MedImmune) in children from 2 through 8 years old, because of evidence of higher efficacy in that age-group.

This year the vast majority of flu vaccine doses the CDC ordered for the Vaccines for Children (VFC) and Section 317 programs are quadrivalent, Santoli reported. She said the agency ordered 19.1 million doses of quadrivalent vaccine and close to 600,000 doses of trivalent vaccine. About 5.3 million doses are FluMist, the nasal spray product.

The VFC and Section 317 programs provide vaccines mainly for low-income, uninsured, and underinsured children.

MedImmune Proudly Supplying 25% of the Welfare Market

 

and we see the purdi little troll dolls dancing for the vaccine marketing landscape report as well. Honestly you are in over your head. Under qualified for your gig. Too bad we can lock meeting room doors to keep you out on breaks, and you all stick out like sore thumbs at conventions. You still Looooove proudly trolling on CP though. funny..

 

To be eligible for Nevada Medicaid reimbursement for flu vaccination you must qualify for a low income eligibility category. Generally, the categories of eligibility
are children, pregnant women, families with dependent children,
disabled adults, or persons age 65 or older. You must be financially eligible for the Nevada Medicaid program to qualify. The rules for assessing your income and assets vary from category to category and are complex. A Division of Welfare and
Supportive Services caseworker will work with you to evaluate
financial eligibility and the programs for which you may be
eligible. There are special rules for persons living in nursing homes
and for disabled children living at home.The flu shot is approved for use among people six months of age or older, including healthy people and those with chronic medical conditions (including asthma, diabetes, and heart disease). A different kind of vaccine, called the nasal-spray flu vaccine (sometimes referred to as LAIV for Live Attenuated Influenza Vaccine or FluMist®), was approved for reimbursement for Medicaid patients and Prisoners of the Nevada State Correctional Facilities. The nasal spray flu vaccine contains attenuated (weakened) live viruses, and is administered by a nasal sprayer. It is approved for use only among non high-risk people aged 2-49 who are not pregnant.